Mays Cancer Center conducts only clinical trial in America of a specific drug combination for lethal brain cancer glioblastoma

May 23, 2023

An improvement in 6-month progression-free survival warrants additional study in a larger trial, researchers said. Contact: Will Sansom, 210-567-2579, sansom@uthscsa.edu SAN ANTONIO (May 23, 2023) — The Mays Cancer Center at The University of Texas Health Science Center at San Antonio recently conducted a clinical trial combining two drugs in patients with recurrent, high-grade glioblastoma […]

Molecule shows potential to combat treatment resistance in brain tumor glioblastoma

May 17, 2023

Glioblastoma-impacted mice lived longer when treated with combination of molecule drug and chemotherapy agent Glioblastoma (GBM), a highly devastating brain tumor, has long posed challenges as effective treatments have remained elusive. Despite responding initially to treatment, GBM patients often experience therapy resistance leading to low long-term survival rates, with only 7.2% of patients surviving beyond […]

Molecule shows potential to combat treatment resistance in brain tumor glioblastoma

May 17, 2023

Glioblastoma-impacted mice lived longer when treated with combination of molecule drug and chemotherapy agent Contact: Will Sansom, 210-567-2579, sansom@uthscsa.edu SAN ANTONIO (May 17, 2023) — Glioblastoma (GBM), a highly devastating brain tumor, has long posed challenges as effective treatments have remained elusive. Despite responding initially to treatment, GBM patients often experience therapy resistance leading to […]